BSE
MARKET ANALYSIS NEWS CORPORATE INFORMATION CORPORATE ACTIONS OTHER MARKETS
Your Result on : Company News Details
Aurobindo Pharma Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
524804
ISIN Demat
INE406A01037
Book Value (Rs)
391.1437121
NSE Symbol
AUROPHARMA
Divident Yield %
0.26
Market Cap
(Rs In Cr.)
89,957
P/E (TTM)
37.04
EPS (TTM)
41.81
Face Value
(Rs)
1
Back
Aurobindo Pharma consolidated net profit rises 1.97% in the March 2026 quarter
22-May-26   Hrs IST

Net profit of Aurobindo Pharma rose 1.97% to Rs 921.26 crore in the quarter ended March 2026 as against Rs 903.47 crore during the previous quarter ended March 2025. Sales rose 4.42% to Rs 8751.50 crore in the quarter ended March 2026 as against Rs 8381.12 crore during the previous quarter ended March 2025.

For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales8751.508381.12 4 33384.7431378.13 6
OPM %20.0021.00 -20.5120.88 -
PBDT1769.181779.52 -1 6955.376715.71 4
PBT1290.611335.09 -3 5177.185066.29 2
NP921.26903.47 2 3504.753485.88 1

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)